Linda-Gail Bekker, PhD, MBChB, DTMH,DCH,FCP(SA)
Deputy Director, Desmond Tutu HIV Centre; President, International AIDS Society
Board member since January 2018
Dr. Linda-Gail Bekker is Deputy Director of the Desmond Tutu HIV Centre at the Institute of Infectious Disease and Molecular Medicine at the University of Cape Town (UCT) and Chief Operating Officer of the Desmond Tutu HIV Foundation. She has been President of the International AIDS Society since 2017.
Dr. Bekker is a physician-scientist and infectious disease specialist focusing on programmatic and action research around antiretroviral roll-out, TB integration, and HIV prevention in key populations. She is principal investigator of the UCT Clinical Trials Unit funded by the U.S. National Institutes of Health (NIH) and is actively involved in the work of its associated clinical research sites and networks. She has chaired protocols for the HIV Vaccine Trials Network and HIV Prevention Trials Network and has been IoR in a number of network-related protocols. She also has served on numerous international and federal scientific and working committees. Bekker leads the Desmond Tutu Centre of Adolescent Health and Wellbeing at UCT, which aims to develop best practices and evidence base around adolescent treatment and prevention of HIV, TB, and STIs, including the integration of these services within a robust, adolescent-friendly, sexual and reproductive service platform.
She holds medical degrees from UCT and a PhD from the Rockefeller University.
Mark B. Feinberg, MD, PhD
As IAVI’s President and CEO, Dr. Mark Feinberg draws on extensive experience in basic, translation, and clinical research and in advancing scientific and public health initiatives for the global control of HIV and other infectious diseases.
Prior to joining IAVI in 2015, Dr. Feinberg served as Chief Public Health and Science Officer with Merck Vaccines where he helped advance research, policy and access efforts for a number of innovative vaccine programs including those targeting rotavirus, human papillomavirus, and shingles. He also led the establishment of the MSD-Wellcome Trust Hilleman Laboratories in India that is dedicated to developing new vaccines to address unmet health needs in low-income countries and the coordination of a private-public partnership to expedite Ebola vaccine development in response to the 2014 Ebola outbreak in West Africa. Previously, he spent more than 20 years exploring HIV/AIDS pathogenesis, treatment, and prevention research and the biology of emerging diseases in both government and academia.
Dr. Feinberg holds an MD and a PhD from Stanford University, and a bachelor’s degree in Biology and Anthropology from the University of Pennsylvania. He pursued post-graduate medical training in Internal Medicine at the Brigham and Women’s Hospital and postdoctoral fellowship training in the laboratory of Dr. David Baltimore at the Whitehead Institute. He has previously served as a faculty member at the University of California, San Francisco, and the Emory University School of Medicine and as a Medical Officer in the Office of AIDS Research at the National Institutes of Health (NIH).
Dr. Feinberg is a Fellow of the American College of Physicians, a member of the Council on Foreign Relations and the Association of American Physicians, and the recipient of an Elizabeth Glaser Scientist Award from the Pediatric AIDS Foundation. He was a Fellow in the Advanced Leadership Initiative at Harvard University. He is Chair of the Scientific Advisory Committee of the Collaboration for Epidemic Preparedness Innovations and a member of the World Bank’s International Task Force on Strengthening Country Capacity for Vaccines Research and Development. He is also a member of the Council of the National Institute of Allergy and Infectious Diseases at the NIH.
The Hon. Mark Dybul, MD
Faculty Co-Director of the Center for Global Health Quality and Professor in the Department of Medicine, Georgetown University Medical Center
Board member since March 2018
Dr. Mark Dybul is the Faculty Co-Director of the Center for Global Health and Quality and Professor in the Department of Medicine at Georgetown University Medical Center.
Mark has worked on HIV and public health for more than 25 years as a clinician, scientist, teacher, and administrator, most recently as the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria.
After graduating from Georgetown Medical School in Washington D.C., Mark joined the National Institute of Allergy and Infectious Diseases, as a research fellow under director Dr. Anthony Fauci, where he conducted basic and clinical studies on HIV virology, immunology and treatment optimization, including the first randomized, controlled trial with combination antiretroviral therapy in Africa.
Mark was one of the founding architects in the formation of the U.S. President’s Emergency Plan for AIDS Relief, better known as PEPFAR. After serving as Chief Medical officer, Assistant, Deputy and Acting Director, he was appointed as its leader in 2006, becoming U.S. Global AIDS Coordinator, with the rank of Ambassador at the level of an Assistant Secretary of State. He served until early 2009.
Mark has written extensively in scientific and policy literature, and has received several Honorary Degrees and awards, including a Doctor of Science, Honoris Causa, from Georgetown University.
Mr. Robert Goldberg is the Chief Operating Officer at Barnard College where he is responsible for the College’s finances, campus services, human resources, and information technology. He also served as Interim President during the spring of 2017.
Previously, Mr. Goldberg completed 25 years of service with the federal government, most recently as the Director of the Office of US Foreign Assistance Resources at the Department of State (2010-2014) where he managed all aspects of the $32 billion foreign assistance budget for the Department and for the US Agency for International Development.
From 1995 to 2014, he served in various roles at the Office of Management and Budget (OMB), including Deputy Associate Director for International Affairs, the senior career official responsible for budget and policy matters related to the US government’s international affairs program; Chief of the Force Structure and Investment Branch of OMB’s National Security Division; and senior budget analyst. His first public sector role was evaluator in the National Security and International Affairs Division of the former General Accounting Office (now Government Accountability Office).
Mr. Goldberg holds both a bachelor’s and a master’s degree in international relations from The George Washington University.
Eric Paul Goosby, MD (Chair)
Director, Center for Implementation Sciences, Global Health Sciences, at the University of California, San Francisco
Board Chair since June 2016; Board Member since 2013
Dr. Eric Goosby has worked in HIV/AIDS research, treatment, advocacy, and policy for more than 25 years and is a leading global expert and champion in fighting the disease. Currently he serves on the board of directors for Friends of the Global Fight Against AIDS, Tuberculosis and Malaria.
As U.S. Global AIDS Coordinator from 2009 to 2013, Dr. Goosby directed the U.S. HIV/AIDS response and led implementation of the President's Emergency Plan for AIDS Relief under President Obama. He also was Founding Director of the Office of Global Health Diplomacy under Secretary of State Hillary Clinton. United Nations Secretary-General Ban Ki-moon appointed him Special Envoy on Tuberculosis in 2015.
He began his career treating HIV/AIDS patients at San Francisco General Hospital, where he was Associate Medical Director from 1984-1991. He joined the U.S. Department of Health and Human Services in 1991 as the first Director of the Ryan White Care Act and served as Deputy Director of the White House National AIDS Policy Office and Director of the Office of HIV/AIDS Policy from 1995-2000. He also was the founding CEO and Chief Medical Officer of Pangaea Global AIDS Foundation.
Dr. Goosby holds an MD from UCSF, where he completed his residency and fellowship specializing in infectious diseases and remained on faculty, receiving a Kaiser Family Foundation Award to support junior faculty. He has published over 250 peer-reviewed publications, numerous technical book chapters, and editorial pieces.
Adel A. F. Mahmoud, MD
Professor, Woodrow Wilson School and Department of Molecular Biology, Princeton University
Board Member since 2012
Dr. Adel Mahmoud is an expert on infectious diseases, global health, and vaccine research and development. He is a fellow of the American College of Physicians and a member of the National Academy of Medicine and the National Academy of Sciences.
Previously, he was President of Merck Vaccines, where he led the effort to develop four new vaccines: Gardasil®, to prevent cervical cancer and other human papillomavirus diseases; RotaTeq®, to prevent infantile rotavirus gastroenteritis; Zostavax®, to prevent shingles; and ProQuad®, to prevent measles, mumps, rubella, and varicella. He also served on the U.S. National Advisory Allergy and Infectious Diseases Council and as President of the Central Society for Clinical Research and the International Society for Infectious Diseases.
Dr. Mahmoud is former Chairman of Medicine and Physician-in-Chief at Case Western University School of Medicine and University Hospitals of Cleveland. He holds both the Bailey K. Ashford Award from the American Society of Tropical Medicine and Hygiene and the Squibb Award from the Infectious Diseases Society of America. He earned an MD from the University of Cairo and a PhD from the University of London, School of Hygiene and Tropical Medicine.
Purnima Mane, PhD, MA, MPhil
Dr. Purnima Mane is an internationally respected expert on sexual and reproductive health and HIV/AIDS. Most recently, she served as the President and CEO of Pathfinder International.
Dr. Mane has held several distinguished posts with the United Nations, including Assistant Secretary-General and Deputy Executive Director of the United Nations Population Fund, and Director of Policy, Evidence and Partnership at the Joint United Nations Programme on HIV/AIDS (UNAIDS). She also served as Chief Fund Portfolio Director and Director, Asia, of the Global Fund to Fight AIDS, Tuberculosis and Malaria; as Vice President and Director of International Programs at the Population Council; and held senior management positions while at the World Health Organization’s Global Programme on AIDS and UNAIDS. Dr. Mane also serves on the Boards of Directors of MTV Staying Alive Foundation and Taking Back Ourselves and is Visiting Professorial Fellow at the Centre for Social Research, University of New South Wales, Australia.
She holds a PhD from Tata Institute of Social Sciences in Mumbai, India, where she was an Associate Professor. Before joining UNAIDS, she worked on public health and gender-related issues in India for over two decades.
Francine Ntoumi, PhD, HDR, PvDz, FRCPedin
Research Group Leader, Institute for Tropical Medicine, University of Tübingen
Board Member since 2015
Dr. Francine Ntoumi is Founder, Chair, and Executive Director of the Fondation Congolaise pour la Recherche Médicale and a malaria expert who advocates for women in science.
Through the Central Africa Network on Tuberculosis, HIV/AIDS and Malaria (CANTAM), Dr. Ntoumi is highly involved in developing African health research capacities, especially for clinical trials. CANTAM is the first African network of excellence supported by the European and Developing Countries Clinical Trials Partnership (EDCTP), of which she is former Senior Scientific Officer. Currently, she is Senior Lecturer in Immunology at Marien Ngouabi University in the Republic of Congo; an Associate Professor at the University of Tübingen in Germany; a member of the Bill & Melinda Gates Foundation’s Global Health Scientific Advisory Board; and a fellow of the African Academy of Sciences. She also holds the distinction of being the Multilateral Initiative on Malaria’s first African leader (2007-2010).
Her accolades include the 2016 Christophe Mérieux Prize, the 2015 Georg Forster Research Award, and the 2012 African Union Kwame Nkrumah Regional Scientific Award for women. She is a laureate of the Réseau International des Congolais de l’Extérieur for her contributions in health research and holds a PhD and Habilitation from Université Pierre et Marie Curie in Paris, France.
Christina Hull Paxson, PhD, MA
Dr. Christina Paxson is a respected economist and public health expert and the nineteenth president of Brown University. Under her leadership, the university has opened a new School of Public Health, launched the Institute at Brown for Environment and Society, and reinvigorated social sciences through its Watson Institute for Public and International Affairs. She also has enhanced financial support, creating centers for first-generation college and low-income students.
Previously, she was dean of the Woodrow Wilson School of Public and International Affairs and the Hughes Rogers Professor of Economics and Public Affairs at Princeton University. Her most recent academic research focuses on the relationship of economic factors to health and welfare over a lifetime, particularly for children. She was principal investigator on several research projects supported by the National Institutes of Health, including a study of adversity and resilience after Hurricane Katrina.
Dr. Paxson is a member of the Council on Foreign Relations, serves on the board of directors of the Federal Reserve Bank of Boston, and is a fellow of the American Academy of Arts and Sciences.
She holds an undergraduate degree from Swarthmore College and earned both a master’s degree and doctorate in economics from Columbia University.
Anne M. VanLent (Vice Chair)
Ms. Anne VanLent is the Founder and President of AMV Advisors, a strategic and financial management consultancy that serves emerging-growth and early stage companies in the life sciences arena. With more than 30 years of leadership experience at research and development, biotechnology, and pharmaceutical firms, Ms. VanLent guides emerging life sciences firms in financial operations, strategic funding and transaction support, and mentoring high-potential executives.
An experienced, seasoned director and audit chair of publicly traded companies, Ms. VanLent currently serves on the Board of Directors of the biopharmaceutical companies Applied Genetic Technologies Corporation and Aviragen Pharmaceuticals, Inc. She also served on the Boards of Novelion Therapeutics, Inc., Ocera Therapeutics, Inc., Onconova Therapeutics, Integra Life Sciences Holding Corporation, and Penwest Pharmaceuticals, among others.
Previously, she was Executive Vice President and Chief Financial Officer of Barrier Therapeutics, Inc., Executive Vice President of Portfolio Management and Vice President of Ventures and Licensing at Sarnoff Corporation, and Executive Vice President and Chief Financial Officer at The Liposome Company, Inc. She holds a bachelor’s degree in physics from Mount Holyoke College.
Dr. Marijke Wijnroks is Interim Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund). The Global Fund raises and invests nearly US$4 billion a year to support programs run by local experts in countries and communities most in need.
She has more than 25 years of experience in global health and development work, serving in the government, at the United Nations and in civil society, and working in Africa, Asia, Latin America, and Europe. Previously, she was Ambassador for HIV/AIDS and Sexual and Reproductive Health and Rights, and Deputy Director of the Social Development Department in the Ministry of Foreign Affairs in the Netherlands. There she oversaw policy and strategy development in areas related to HIV/AIDS, sexual and reproductive health and rights, and civil society; advised senior leadership on development and health issues; and represented the Dutch government on the boards of several leading organizations, including the Global Fund, Gavi, and UNAIDS.
She earned a medical degree from Maastricht University in the Netherlands and a degree in tropical health and medicine from the Institute for Tropical Medicine in Belgium.